1. Home
  2. FMS vs CYTK Comparison

FMS vs CYTK Comparison

Compare FMS & CYTK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Fresenius Medical Care AG

FMS

Fresenius Medical Care AG

N/A

Current Price

$24.58

Market Cap

13.0B

Sector

Health Care

ML Signal

N/A

Logo Cytokinetics Incorporated

CYTK

Cytokinetics Incorporated

N/A

Current Price

$80.74

Market Cap

10.7B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
FMS
CYTK
Founded
1996
1997
Country
Germany
United States
Employees
108165
N/A
Industry
Misc Health and Biotechnology Services
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
13.0B
10.7B
IPO Year
N/A
2004

Fundamental Metrics

Financial Performance
Metric
FMS
CYTK
Price
$24.58
$80.74
Analyst Decision
Sell
Strong Buy
Analyst Count
2
19
Target Price
$30.00
$89.26
AVG Volume (30 Days)
577.2K
1.8M
Earning Date
05-05-2026
05-05-2026
Dividend Yield
2.57%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$13,368,000.00
Revenue This Year
N/A
$7.37
Revenue Next Year
$3.83
$310.19
P/E Ratio
$15.62
N/A
Revenue Growth
N/A
N/A
52 Week Low
$20.02
$32.89
52 Week High
$27.64
$88.31

Technical Indicators

Market Signals
Indicator
FMS
CYTK
Relative Strength Index (RSI) 65.50 53.54
Support Level $22.47 $59.07
Resistance Level $27.40 $88.31
Average True Range (ATR) 0.29 2.90
MACD 0.02 -0.56
Stochastic Oscillator 97.64 45.23

Price Performance

Historical Comparison
FMS
CYTK

About FMS Fresenius Medical Care AG

Fresenius Medical Care is the largest dialysis company in the world, treating nearly 300,000 patients from about 3,600 clinics worldwide as of December 2025. In addition to providing dialysis services, the firm is a leading supplier of dialysis products, including machines, dialyzers, and concentrates. Fresenius accounts for about 35% of the global dialysis products market, creating the world's only fully integrated dialysis business. Services account for about three-fourths of sales, while the balance is generated from medical technology products that enable dialysis treatments.

About CYTK Cytokinetics Incorporated

Cytokinetics Inc is a late-stage biopharmaceutical company focused on discovering, developing, and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary disease. The company's product, named as MYQORZO, is an allosteric and reversible inhibitor of cardiac myosin motor activity. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.

Share on Social Networks: